UTMD UTAH MEDICAL PRODUCTS INC
Updated
Healthcare · Surgical & Medical Instruments & Apparatus
UTAH MEDICAL PRODUCTS INC (UTMD) is a healthcare company in the Surgical & Medical Instruments & Apparatus industry, with a market capitalization of $226 million. Shares last traded at $70.89, 6.7% below their 52-week high. Over the past year the stock is up 16.3%. UTMD trades at a price-to-earnings ratio of 21.52, below the Surgical & Medical Instruments & Apparatus median of 28.18. Net profit margin is 29.0%, above the peer median of -9.3%. Revenue declined 5.8% year over year.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
UTMD Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $4M | $0.00 | 35% |
| 2024-12-31 | $4M | $0.00 | 31% |
| 2023-12-31 | $4M | $0.00 | 26% |
| 2022-12-31 | $3M | $0.00 | 19% |
| 2021-12-31 | $11M | $0.00 | 78% |
| 2020-12-31 | $4M | $0.00 | 38% |
| 2019-12-31 | $4M | $0.00 | 28% |
| 2018-12-31 | $4M | $0.00 | 22% |
| 2017-12-31 | $3M | $0.00 | 35% |
| 2016-12-31 | $4M | $0.00 | 32% |
| 2015-12-31 | $4M | $0.00 | 32% |
| 2014-12-31 | $4M | $0.00 | 33% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $1.66 | 2026-08-12 |
| Q1 2026 | $0.82 | 2026-05-12 |
| FY 2025 | $3.48 | 2026-03-27 |
| FY 2025 | $0.82 | 2026-03-27 |
| Q2 2026 | $1.86 | 2026-08-12 |
| Q1 2026 | $0.92 | 2026-05-12 |
Surgical & Medical Instruments & Apparatus peers
UTMD vs 14 industry peers (Surgical & Medical Instruments & Apparatus), by market cap. Updated
| SYK | Stryker Corporation | $118.2B | 31.69 | 4.57 | 14.4% | -1.31% |
| MMM | 3M | $86.8B | 28.97 | 3.45 | 11.9% | -0.28% |
| BSX | Boston Scientific | $68.0B | 18.54 | 3.24 | 17.5% | -3.17% |
| BDX | Becton Dickinson | $51.1B | 54.30 | 2.45 | 4.5% | +0.00% |
| DXCM | DexCom | $33.9B | 33.86 | 6.81 | 20.1% | +0.02% |
| RMD | ResMed | $33.1B | 21.70 | 5.85 | 26.9% | -0.78% |
| MDLN | Medline Inc. | $30.7B | — | 1.08 | — | +0.88% |
| WST | West Pharmaceutical Services | $24.1B | 42.67 | 7.25 | 17.0% | +0.00% |
| SOLV | Solventum | $15.7B | 10.97 | 1.89 | 17.3% | +0.56% |
| BAX | Baxter International | $13.2B | -12.44 | 1.15 | -9.3% | -0.51% |
| PEN | Penumbra Inc | $12.7B | 78.81 | 9.02 | 11.4% | -0.46% |
| GKOS | Glaukos Corp | $10.6B | -56.59 | 17.36 | -30.7% | +0.52% |
| GMED | Globus Medical Inc | $10.5B | 19.59 | 3.34 | 17.0% | -3.14% |
| PODD | Insulet Corporation | $10.4B | 27.82 | 3.42 | 12.3% | +1.63% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.